Programs

Surrozen is developing a broad pipeline of disease-specific antibodies to help gravely ill patients across multiple disease areas.

Our strategy is to harness the full breadth of Wnt potential by identifying disease states responsive to Wnt pathway modulation, design tissue-specific antibodies, and advance candidates into clinical development in indications with high unmet need.

The following table highlights our lead programs.

Lead Programs

Indication(s)

Research

Preclinical

Phase 1

Phase 2

Phase 3

Indication

Status / Upcoming Milestones

Partnerships

Status

SZN-043
Severe Alcoholic Hepatitis
Ph 1 Ongoing
SZN-1326
Moderate to Severe IBD
Enrollment paused: Next Steps TBD


The following table highlights our identified research programs.

Research Programs

Tissue

Indications

Discovery

Proof of Concept

Lead Candidate/s

Status

Lung
IPF
Discovery
Lacrimal Gland
Severe Dry Eye (Sjögren’s)
Discovery
Cornea
Fuchs' Dystrophy
Discovery
Lung
COPD
Discovery
Pancreas
Type 1 Diabetes
Discovery
Skin
Wound Healing
Discovery

IBD: Inflammatory Bowel Disease; IPF: Idiopathic Pulmonary Fibrosis; COPD: Chronic Obstructive Pulmonary Disease

Surrozen’s novel approach to modulating the Wnt pathway may lead to therapeutics that reverse the effects of serious diseases by repairing damaged tissue, restoring organ function and renewing a patient’s health, and hope, for an improved quality of life.

Repair. Restore. Renew.